Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients

Seul Kee Byeon, Se Hee Park, Jong Cheol Lee, Sena Hwang, Cheol Ryong Ku, Dong Yeob Shin, Jin Sook Yoon, Eun Jig Lee, Myeong Hee Moon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Approximately 50% of patients with Graves’ disease (GD) develop retracted eyelids with bulging eyes, known as Graves’ ophthalmopathy (GO). However, no simple diagnostic blood marker for distinguishing GO from GD has been developed yet. The objective of this study was to conduct comprehensive profiling of lipids using plasma and urine samples from patients with GD and GO undergoing antithyroid therapy using nanoflow ultrahigh performance liquid chromatography electrospray ionization tandem mass spectrometry. Plasma (n = 86) and urine (n = 75) samples were collected from 23 patients with GD without GO, 31 patients with GO, and 32 healthy controls. Among 389 plasma and 273 urinary lipids that were structurally identified, 281 plasma and 191 urinary lipids were quantified in selected reaction monitoring mode. High-abundance lipids were significantly altered, indicating that the development of GD is evidently related to altered lipid metabolism in both plasma and urine. Several urinary lysophosphatidylcholine species were found to be increased (3- to 10-fold) in both GD and GO. While the overall lipid profiles between GD and GO were similar, significant changes (area under receiver operating curve > 0.8) in GO vs. GD were observed in a few lipid profiles: 58:7-TG and (16:1,18:0)-DG from plasma, 16:1-PC and 50:1-TG from urine, and d18:1-S1P from both plasma and urine samples. An altered metabolism of lipids associated with the additional development of ophthalmopathy was confirmed with the discovery of several candidate markers. These can be suggested as candidate markers for differentiating the state of GO and GD patients based on plasma or urinary lipidomic analysis. [Figure not available: see fulltext.].

Original languageEnglish
Pages (from-to)7121-7133
Number of pages13
JournalAnalytical and Bioanalytical Chemistry
Volume410
Issue number27
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Graves Ophthalmopathy
Graves Disease
Urine
Plasmas
Lipids
Lipid Metabolism
Electrospray ionization
Lysophosphatidylcholines
Electrospray Ionization Mass Spectrometry
Liquid chromatography
Eyelids
Tandem Mass Spectrometry
Metabolism
Liquid Chromatography
Mass spectrometry
Blood

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry

Cite this

Byeon, Seul Kee ; Park, Se Hee ; Lee, Jong Cheol ; Hwang, Sena ; Ku, Cheol Ryong ; Shin, Dong Yeob ; Yoon, Jin Sook ; Lee, Eun Jig ; Moon, Myeong Hee. / Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients. In: Analytical and Bioanalytical Chemistry. 2018 ; Vol. 410, No. 27. pp. 7121-7133.
@article{518b38c179054b1e94e3e6723a90b559,
title = "Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients",
abstract = "Approximately 50{\%} of patients with Graves’ disease (GD) develop retracted eyelids with bulging eyes, known as Graves’ ophthalmopathy (GO). However, no simple diagnostic blood marker for distinguishing GO from GD has been developed yet. The objective of this study was to conduct comprehensive profiling of lipids using plasma and urine samples from patients with GD and GO undergoing antithyroid therapy using nanoflow ultrahigh performance liquid chromatography electrospray ionization tandem mass spectrometry. Plasma (n = 86) and urine (n = 75) samples were collected from 23 patients with GD without GO, 31 patients with GO, and 32 healthy controls. Among 389 plasma and 273 urinary lipids that were structurally identified, 281 plasma and 191 urinary lipids were quantified in selected reaction monitoring mode. High-abundance lipids were significantly altered, indicating that the development of GD is evidently related to altered lipid metabolism in both plasma and urine. Several urinary lysophosphatidylcholine species were found to be increased (3- to 10-fold) in both GD and GO. While the overall lipid profiles between GD and GO were similar, significant changes (area under receiver operating curve > 0.8) in GO vs. GD were observed in a few lipid profiles: 58:7-TG and (16:1,18:0)-DG from plasma, 16:1-PC and 50:1-TG from urine, and d18:1-S1P from both plasma and urine samples. An altered metabolism of lipids associated with the additional development of ophthalmopathy was confirmed with the discovery of several candidate markers. These can be suggested as candidate markers for differentiating the state of GO and GD patients based on plasma or urinary lipidomic analysis. [Figure not available: see fulltext.].",
author = "Byeon, {Seul Kee} and Park, {Se Hee} and Lee, {Jong Cheol} and Sena Hwang and Ku, {Cheol Ryong} and Shin, {Dong Yeob} and Yoon, {Jin Sook} and Lee, {Eun Jig} and Moon, {Myeong Hee}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s00216-018-1313-2",
language = "English",
volume = "410",
pages = "7121--7133",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",
number = "27",

}

Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients. / Byeon, Seul Kee; Park, Se Hee; Lee, Jong Cheol; Hwang, Sena; Ku, Cheol Ryong; Shin, Dong Yeob; Yoon, Jin Sook; Lee, Eun Jig; Moon, Myeong Hee.

In: Analytical and Bioanalytical Chemistry, Vol. 410, No. 27, 01.11.2018, p. 7121-7133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients

AU - Byeon, Seul Kee

AU - Park, Se Hee

AU - Lee, Jong Cheol

AU - Hwang, Sena

AU - Ku, Cheol Ryong

AU - Shin, Dong Yeob

AU - Yoon, Jin Sook

AU - Lee, Eun Jig

AU - Moon, Myeong Hee

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Approximately 50% of patients with Graves’ disease (GD) develop retracted eyelids with bulging eyes, known as Graves’ ophthalmopathy (GO). However, no simple diagnostic blood marker for distinguishing GO from GD has been developed yet. The objective of this study was to conduct comprehensive profiling of lipids using plasma and urine samples from patients with GD and GO undergoing antithyroid therapy using nanoflow ultrahigh performance liquid chromatography electrospray ionization tandem mass spectrometry. Plasma (n = 86) and urine (n = 75) samples were collected from 23 patients with GD without GO, 31 patients with GO, and 32 healthy controls. Among 389 plasma and 273 urinary lipids that were structurally identified, 281 plasma and 191 urinary lipids were quantified in selected reaction monitoring mode. High-abundance lipids were significantly altered, indicating that the development of GD is evidently related to altered lipid metabolism in both plasma and urine. Several urinary lysophosphatidylcholine species were found to be increased (3- to 10-fold) in both GD and GO. While the overall lipid profiles between GD and GO were similar, significant changes (area under receiver operating curve > 0.8) in GO vs. GD were observed in a few lipid profiles: 58:7-TG and (16:1,18:0)-DG from plasma, 16:1-PC and 50:1-TG from urine, and d18:1-S1P from both plasma and urine samples. An altered metabolism of lipids associated with the additional development of ophthalmopathy was confirmed with the discovery of several candidate markers. These can be suggested as candidate markers for differentiating the state of GO and GD patients based on plasma or urinary lipidomic analysis. [Figure not available: see fulltext.].

AB - Approximately 50% of patients with Graves’ disease (GD) develop retracted eyelids with bulging eyes, known as Graves’ ophthalmopathy (GO). However, no simple diagnostic blood marker for distinguishing GO from GD has been developed yet. The objective of this study was to conduct comprehensive profiling of lipids using plasma and urine samples from patients with GD and GO undergoing antithyroid therapy using nanoflow ultrahigh performance liquid chromatography electrospray ionization tandem mass spectrometry. Plasma (n = 86) and urine (n = 75) samples were collected from 23 patients with GD without GO, 31 patients with GO, and 32 healthy controls. Among 389 plasma and 273 urinary lipids that were structurally identified, 281 plasma and 191 urinary lipids were quantified in selected reaction monitoring mode. High-abundance lipids were significantly altered, indicating that the development of GD is evidently related to altered lipid metabolism in both plasma and urine. Several urinary lysophosphatidylcholine species were found to be increased (3- to 10-fold) in both GD and GO. While the overall lipid profiles between GD and GO were similar, significant changes (area under receiver operating curve > 0.8) in GO vs. GD were observed in a few lipid profiles: 58:7-TG and (16:1,18:0)-DG from plasma, 16:1-PC and 50:1-TG from urine, and d18:1-S1P from both plasma and urine samples. An altered metabolism of lipids associated with the additional development of ophthalmopathy was confirmed with the discovery of several candidate markers. These can be suggested as candidate markers for differentiating the state of GO and GD patients based on plasma or urinary lipidomic analysis. [Figure not available: see fulltext.].

UR - http://www.scopus.com/inward/record.url?scp=85052308256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052308256&partnerID=8YFLogxK

U2 - 10.1007/s00216-018-1313-2

DO - 10.1007/s00216-018-1313-2

M3 - Article

C2 - 30135996

AN - SCOPUS:85052308256

VL - 410

SP - 7121

EP - 7133

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

IS - 27

ER -